1st Patient Enrolled in PARI PROVIDE; New Compressor Access Program for Kitabis Pak Patients

RICHMOND, Va., Feb. 11, 2015 /PRNewswire/ -- The first patient has been enrolled in the PARI PROVIDE compressor access program to accompany the launch of Kitabis Pak.  FDA approved Kitabis Pak as a drug and device combination - the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS^® Nebulizer for patients with cystic fibrosis.

"Kitabis Pak makes taking nebulized tobramycin easier because it is one prescription for both the drug and nebulizer handset.  Distribution delays are eliminated because both the drug and nebulizer handset are dispensed together. PARI PROVIDE takes the program one step further by providing patients with the only FDA approved compressor to deliver tobramycin inhalation solution," explained Geoff Hunziker, president of PARI USA.

Cystic fibrosis patients often take multiple inhaled medications where a compressor is needed to power the nebulization of liquid medication and turn it into an inhalable mist.

"It is important for patients to know that tobramycin inhalation solution is only approved for use with the nebulizer handset in Kitabis Pak and the compressor included in PARI PROVIDE.  A lot of work went into the original clinical trials.  The components of Kitabis Pak and PARI PROVIDE give patients with cystic fibrosis full access to what the FDA approved as an effective inhaled antibiotic therapy," said Lisa Cambridge, director of Medical Science at PARI Respiratory USA.

PARI Respiratory exclusively markets Kitabis Pak and the compressor access program called PARI PROVIDE.  Kitabis Pak is a new standard for nebulized drugs similar to asthma & COPD inhalers where the drug and device are prescribed and dispensed together.  The price of Kitabis Pak is comparable to the price of generic tobramycin drug alone.

About Kitabis Pak
KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.  Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Full product and prescribing information on Kitabis Pak and PARI PROVIDE is online at: www.Kitabis.com.

About Cystic Fibrosis
Cystic fibrosis, a life-threatening disease affecting 30,000 American patients, involves a genetic mutation that results in poorly hydrated, thickened mucus secretions in the lungs.

About PARI Respiratory Equipment, Inc.
PARI is a leading, worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, cystic fibrosis, RSV, VAP, and HAP.  PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them. PARI is considered the gold standard for aerosol delivery for nebulizer therapies.  Featured products include the PARI LC PLUS Reusable Nebulizer, Vortex Holding Chamber, and the drug-specific eFlow Technology platform.

SOURCE PARI Respiratory Equipment